Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?
Royalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.
How this was made
The 30-second read
Why it matters
The financing expands RPRX's royalty assets, likely supporting a short‑term price rally.
Market read
A sizable royalty deal that could shift RPRX's valuation and attract income‑focused investors.
What to watch
Potential regulatory or pricing risk for rusfertide could affect royalty payouts.
Background
The article reviews the new royalty financing deal and its valuation implications for Royalty Pharma.
Ticker impact
Royalty Pharma agreed to provide $100 million to Zealand Pharma for economic rights to the rusfertide royalty.
Potential upside of 5‑8% as investors price in higher royalty income.
Large financing deal is material for a mid‑cap royalty company and is likely to be priced in quickly.
Market effects
Adds to demand for royalty‑based financing in rare‑disease biotech.
May influence European biotech funding dynamics, given Zealand Pharma is Denmark‑based.
Highlights growing investor appetite for royalty streams across biotech.
Counterpoint
Deal could dilute RPRX's balance sheet if future royalty cash flows underperform expectations.
Key entities
- CompanyRoyalty Pharma
US‑listed royalty finance company (ticker RPRX).
- CompanyZealand Pharma
Danish biotech developing rusfertide for polycythemia vera.
